FDA approves tirzepatide to cut cardiovascular risk in type 2 diabetes
The label expansion moves Eli Lilly's dual GIP/GLP-1 agonist beyond glycemic control into cardiovascular risk reduction.
DO
By Daniel Okafor · Regulatory Correspondent
Aug 28 03:00 ETSource: hcplive.com
The wire
- 01The FDA approved tirzepatide for reducing cardiovascular risk in adults with type 2 diabetes, according to HCPLive.
- 02A cardiovascular indication strengthens the case for coverage and prescribing in patients with established risk, and puts tirzepatide on a footing closer to semaglutide's CV labeling.
- 03The specific endpoints, trial population and any restrictions in the approved language should be checked against the updated prescribing information.
From the source
Read at hcplive.comTirzepatide Gets FDA Approval to Cut Cardiovascular Risk in Type 2 Diabetes
